



Sociedad Argentina de Terapia Radiante Oncológica

Best of ASTRO en Argentina



SCIENCE OF TODAY
HOPE FOR TOMORROW

18 y 19 de Mayo de 2017

**Hotel Melia Buenos Aires, Reconquista 945
Ciudad Autónoma de Buenos Aires**

07:15 – 8:15 hs. **Acreditación**

08:20 – 08:50 hs. **Bienvenida**

Dra. Luisa Rafailovici, Directora Best of ASTRO – Presidente SATRO

Dr. Eduardo Fernández, Co-Director Best of ASTRO

Prof Dr. Miguel Galmés, Presidente de la Asociación Médica Argentina

Dr. Roberto Pradier, Director del Instituto Nacional del Cáncer

08:50 – 10:15 hs. **Módulo 1: Mama**

08:50 – 08:55 hs. **Presidente:** A Confirmar

Coordinador: Dr. Hugo Marsiglia, Instituto Oncológico FALP, Chile

Disertantes:

08:55 – 09:10 hs. **Dra. Luisa Rafailovici, Vidt Centro Médico, Buenos Aires**

- **Abstract 1: (324)** Radiation Boost for Ductal Carcinoma In Situ After Whole-breast Radiation Therapy (WBRT) Improves Local Control: Analysis From 10 Pooled Academic Institutions
- **Abstract 2: (9)** Efficacy of Mometasone Furoate in the Reduction of Moderate/Severe Radiation Dermatitis in Breast Cancer Patients Following Mastectomy
- **Abstract 3: (12)** Longitudinal Analysis of Patient-reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-breast Irradiation

09:10 – 09:25 hs. **Dr. Pedro Kasdorf, Inst. Nacional del Cáncer, Montevideo, Uruguay**

- **Abstract 4: (1099)** The Effect of Breast Irradiation on Cardiac Disease in Women Enrolled on BCIRG-001 at 10-Year Follow-up
- **Abstract 5: (327)** Regional Patterns of Breast Cancer Failure After Definitive Therapy: A Large, Single-institution Analysis
- **Abstract 6: (329)** The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients with Node-positive Breast Cancer Treated on SWOG S8814

09:25 – 09:35 hs. **Dra. Verónica Vázquez Balcarce, Vidt Centro Médico, Bs As**

- **Abstract 7: (331)** CD47 as a Target for Immune-radiation Therapy for HER2-Expressing Breast Cancer Cells
- **Abstract 8: (10)** Ten-year Results of the Breast Intensity Modulated Radiation Therapy (IMRT) Randomized Controlled Trial

09:35 – 10:15 hs. **Mesa de Discusión**

Coordinador: Dr. Hugo Marsiglia

Dra. Claudia De Angelis (RT), Dra. Luisa Rafailovici (RT),

Dr. Pedro Kasdorf (RT), Dra. Verónica Vázquez Balcarce (RT)

Dr. Gonzalo Rubio, Oncología Clínica, Academia Nacional de Medicina Patología Mamaria (A Confirmar)

10:15 – 10:50 hs. Módulo 2: Física

10:15 – 10:20 hs. Presidente y Coordinador:

Lic. Víctor Bourel, Universidad Favaloro, Buenos Aires

Disertantes:

10:20 – 10:25 hs. Lic. Mariana Casal, Instituto Ángel Roffo, Buenos Aires

- **Abstract 1: (102)** Selection of FDG Positron Emission Tomography-based Bioparametric Matrixes for Tumor Dose Response Mapping and Adaptive Dose Painting by Number

10:25 – 10:30 hs. Lic. Karla Torzsok, Instituto Oncológico FALP, Chile

- **Abstract 2: (104)** First Clinical Implementation of Electromagnetic Transponder-guided MLC Tracking for Lung Stereotactic Ablative Radiation Therapy

10:30 – 10:40 hs. Lic. Diego Franco, Centro Med. Dean Funes, Córdoba

- **Abstract 3: (99)** Reinforcement Learning Strategies for Decision Making in Knowledge-based Adaptive Radiation Therapy: Application in Liver Cancer
- **Abstract 4: (106)** Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy (SABR) for Lung Cancer: Physician Performance Versus Radiomic Assessment

10:40 – 10:50 hs. Comentarios Finales Lic. Víctor Bourel

10:50 – 11:20 hs. Intervalo Café

11:20 – 12:45 hs. *Módulo 3: Pulmón*

11:20 – 11:25 hs. **Presidente:** Dr. Aldo Quarneti, Hospital Británico, Montevideo, Uruguay

Coordinadora: Dra. Berta Roth, Instituto Ángel Roffo, Buenos Aires

Disertantes:

11:25 – 11:40 hs. **Dr. Gustavo Ferraris, Centro Médico Dean Funes, Córdoba**

- **Abstract 1: (16)** Efficacy and Toxicity Analysis of NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-small Cell Lung Cancer (NSCLC)
- **Abstract 2: (17)** A Phase 2 Randomized Study of two Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node-negative, Peripheral Non-small Cell Lung Cancer
- **Abstract 3: (348)** Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose in Unresectable Stage III Non-small Cell Lung Cancer

11:40 – 11:55 hs. **Dra. María Luisa Filomia, Vidt Centro Médico, Buenos Aires**

- **Abstract 4: (346)** Identifying Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit from Intensive Radiation Therapy
- **Abstract 5: (155)** The Differential Impact of Postoperative Radiation Therapy for Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer: Based on the Risk Prediction Model for Locoregional Recurrence
- **Abstract 6: (350)** Role of Surveillance Imaging Versus Symptoms and Signs in Detection of Recurrence of Non-small Cell Lung Cancer After Curative Intent Therapy

11:55 – 12:05 hs. **Dr. Carlos Pizzo, Terapia Radiante cumbres, Rosario, Sta. Fe.**

- **Abstract 7: (291)** Impact of Incidental Cardiac Radiation on Cardiopulmonary Toxicity and Survival for Locally Advanced Non-small Cell Lung Cancer: Reanalysis of NRG Oncology/RTOG 0617 with Centrally Contoured Cardiac Structures
- **Abstract 8: (293)** Radiation Dose to the Thoracic Vertebral Bodies is Associated with Acute Hematologic Toxicity in Patients Receiving Concurrent Chemoradiation for Lung Cancer

12:05 – 12:45 hs. **Mesa de Discusión**

Coordinadora: Dra. Berta Roth

Dr. Aldo Quarneti (RT), Dra. María Luisa Filomia (RT)

Dr. Gustavo Ferraris (RT), Dr. Carlos Pizzo (RT)

Dr. Gonzalo Recondo, Oncología Clínica, CEMIC, Buenos Aires

12:45 – 14:15 hs. *Almuerzo Libre*

Capítulo SATRO Jóvenes Radioterapeutas

14:15 – 15:40 hs. Módulo 4: Cuidados Paliativos

14:15 – 14:20 hs. Presidente: Dr. Rubén Darío Llanos, Centro de Radioterapia, San Juan

Coordinadores: Dr. José Máximo Barros,
Centro de Radioterapia Hospital Austral, Bs. As.
Dra. Lijia Aviles, Vidt Centro Médico, Buenos Aires

Disertantes:

14:20 – 14:30 hs. Dr. Federico Díaz, Instituto Mevaterapia, Buenos Aires

- **Abstract 1: (334)** Palliative Care Education in Radiation Oncology Training Programs Across the United States: A Program Directors' Survey
- **Abstract 2: (1072)** The TEACHH Model: Clinical Utility of Identifying Patients Living Fewer Than Two Months

14:30 – 14:40 hs. Dr. Ignacio Sisamon, Centro de Oncol. y RT, Mar del Plata, Bs As

- **Abstract 3: (1079)** Hemostatic Radiation Therapy for Malignant Tumors—A Retrospective Analysis of Bleeding Resolution Rate
- **Abstract 4: (1074)** Consideration of Patient and Disease Characteristics in Selecting Radiation Regimens for Treatment of Bone Metastases

14:40 – 14:50 hs. Dra. Angélica Molina, Instituto Ángel Roffo, Buenos Aires

- **Abstract 5: (333)** Recursive Partitioning Analysis is Predictive of Overall Survival for Patients Undergoing Spine Radiosurgery for Spine Metastasis
- **Abstract 6: (339)** Diagnostic Computed Tomography (CT)-based Preplanning Coupled with Post-treatment Cone Beam CT Dosimetry Allows for Rapid, Safe, Image Guided Delivery of Emergent Radiation Therapy

14:50 – 15:00 hs. Dra. María José Girola, Vidt Centro Médico, Buenos Aires

- **Abstract 7: (336)** Clinical Outcomes of Palliative Radiation Therapy for Pediatric Oncology Patients
- **Abstract 8: (1077)** Quality of Life Outcomes Following Spine Stereotactic Radiosurgery

15:00 – 15:40 hs. Mesa de Discusión

Coordinadores: Dr. Jose Máximo Barros, Dra. Lijia Aviles
Dr. Rubén Darío Llanos, Dr. Federico Díaz, Dr. Ignacio Sisamon
Dra. Angela Molina, Dra. María José Girola
Mariana Pérez de Antueno, Vidt Centro Médico, Buenos Aires

15:40 – 16:15 hs. Modulo 5: Seguridad del Paciente

15:40 – 15:45 hs. Presidente: Lic. María del Pilar Duran, Vidt Centro Médico, Buenos Aires

Coordinadora: Lic. Karla Torzsok, Instituto Oncológico FALP, Chile

Disertantes:

15:45 – 16:05 hs. Lic. Liliana Mairal, Centro Médico Mevaterapia, Buenos Aires

- **Abstract 1: (163)** Indicators of Safety-critical Events in Radiation Oncology Derived from the Oncology Information System
- **Abstract 2: (165)** Computerized System for Safety Verification of External Beam Radiation Therapy Planning
- **Abstract 3: (166)** Improvements in Clinical Workflow Measures and Clinician Group Performance Following Implementation of a Physician Dashboard Monitoring and Feedback Process
- **Abstract 4: (167)** Clinical Pathways—A Step to Further Improve Implementation of Quality Radiation Delivery for Breast Cancer

16:05 – 16:15 hs. Comentarios Finales Lic. Karla Torzsok

16:15 – 16:45 hs. Intervalo Café

16:45 – 18:10 hs. Módulo 6: Linfoma / Leucemia

16:45 – 16:50 hs. Presidente: Dr. Ricardo Alva, Hospital Naval, Buenos Aires

Coordinador:

Dr. Mario Di Nucci,
Centro de Oncología y Radioterapia, Mar del Plata, Pcia. Bs. As.

Disertantes:

16:50 – 17:00 hs. Dra. Patricia Bruno Centro de Oncología y RT, V. María, Córdoba

- **Abstract 1: (41)** Combined Modality Therapy for Early-stage Grade 3 Follicular Lymphoma Improves Overall Survival
- **Abstract 2: (88)** Consolidation Radiation Therapy Improves Outcome of Diffuse Large B-cell Lymphoma Independent of Pretreatment Prognosis or Response to Chemotherapy

17:00 – 17:10hs. Dr. Juan José Galarraga,

Centro de Oncología y RT, Mar del Plata, Pcia. Bs. As.

- **Abstract 3: (1008)** Prognostic Significance of the Postchemotherapy Positron Emission Tomography (PET)/Computed Tomography in Early-stage Hodgkin's Lymphoma: Can PET-positive Patients Be Cured with Radiation Alone?
- **Abstract 4: (44)** Utilization of Positron Emission Tomography/Computed Tomography Parameters to Identify Patients at Risk for Progression After Treatment with Dose-adjusted R-EPOCH for Primary Mediastinal B-Cell Lymphoma (PMBCL)

17:10 – 17:20 hs. Dr. Oscar Gómez Orrego, Centro de Radioterapia San Martín, Bs. As.

- **Abstract 5: (86)** Spatial Patterns of Local Failure Following Chemotherapy in Hodgkin's Lymphoma: Volume Reduction from Involved Site/Nodal Radiation Therapy
- **Abstract 6: (45)** Brentuximab Vedotin and AVD Chemotherapy Followed by ISRT: A Safe Primary Treatment Regimen for Early-stage, Unfavorable Hodgkin's Lymphoma

17:20 – 17:30 hs. Dr. Luis Reñe, Centro de Radioterapia, Rosario, Provincia de Sta. Fe

- **Abstract 7: (47)** Modulated Radiation Therapy by Tomotherapy (IMRT) Concurrent with a Short Systemic Treatment for Solitary Plasmacytoma of the Bone (SPB) with Improvement of Progression-free Survival
- **Abstract 8: (84)** A Prospective Pilot Study Evaluating Feasibility and Utility of ECG-gated CT Angiography for Coronary-sparing Radiation Therapy Planning in Mediastinal Lymphoma

17:30 – 18:10 hs. Mesa de Discusión

Coordinador: Dr. Mario Di Nucci
Dra. Patricia Bruno, Dr. Juan José Galarraga,
Dr. Oscar Gómez Orrego, Dr. Luis Reñe

18:10 – 19:10 hs. Sesión Educativa
Oropharyngeal Guideline and APBI Consensus Statement Updates

18:10 – 18:15 **Presidente:** Dr. Miguel Torres, Centro C.O.R., Montevideo, Uruguay

18:15 – 18:35 ***Disertante Oropharyngeal Guideline:***
Dr. Jorge Palazzo, Vidt Centro Médico, Tucumán

18:35 – 18:55 ***Disertante APBI Consensus Statement Updates:***
Dra. María Fernanda Díaz Vázquez
Centro Médico Dean Funes, Córdoba

18:55 – 19:10 **Preguntas del público**

8:00 – 12:00 hs. **Acreditación**

09:00 – 10:25 hs. **Módulo 7: Gastrointestinal**

09:00 – 09:05 hs. **Presidente:** Dr. Andrés Salum, Centro de Oncología Radiante, Jujuy

Coordinadora:

Dra. Higinia Cardenes, Weill Cornell University, New York, USA

Disertantes:

09:05 – 09:20 hs. **Dra. Claudia Benavento, Hospital B. Rivadavia, Buenos Aires**

- **Abstract 1: (243)** The Initial Results for a Phase 3 Study of Short-term Versus Long-term Chemoradiation Therapy in Locally Advanced Rectal Cancer (STELLAR Trial)
- **Abstract 2: (241)** Phase 1 Study of Trametinib and Neoadjuvant Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC) with KRAS, BRAF or NRAS Mutations
- **Abstract 3: (1062)** Impact of Radiation Dose Escalation for Cervical Esophageal Cancer: A National Cancer Data Base (NCDB) Analysis

09:20 – 09:35 hs. **Dr. Marcelo Andrade Irusta, Instituto CEMIC, Buenos Aires**

- **Abstract 4: (70)** A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results
- **Abstract 5: (68)** Patient-reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Esophageal Cancer Treated without Surgery
- **Abstract 6: (1)** Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC)

09:35 – 09:45 hs. **Dra. Mabel Sardi, Instituto Mevaterapia, Buenos Aires**

- **Abstract 7: (322)** Combined Analysis of Two Prospective Trials of Individualized Adaptive Stereotactic Body Radiation Therapy for the Treatment of Hepatocellular Carcinoma (HCC) or Liver Metastases
- **Abstract 8: (323)** Protocol RAD 0902: A Pilot Study of Transarterial Chemoembolization Followed by Stereotactic Radiation Therapy for Locally Advanced Hepatocellular Carcinoma

09:45 – 10:25 hs. **Mesa de Discusión**

Coordinadora: Dr. Higinia Cardenes

Dr. Andrés Salum (RT), Dra. Claudia Benavento (RT),

Dr. Marcelo Andrade Irusta (RT), Dra. Mabel Sardi (RT)

Dr. Mario Barugel, Oncología Clínica, Hosp. Gastroenterología Udaondo

10:25 – 11:50 hs. Módulo 8: Cabeza y Cuello

10:25 – 10:30 hs. Presidente: Dra. Cecilia Coll, Instituto de Radioterapia Cuyo, Mendoza

Coordinador: Dr. Marcos David Pereira, Instituto Ángel Roffo, Bs. As.

Disertantes:

10:30 – 10:40 hs. Dr. Carlos Donoso, Vidt Centro Médico, Buenos Aires

- **Abstract 1: (2797)** Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy with or without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): Seven-year Survival Data from a Phase 3 Randomized Trial and Prognostic Factors
- **Abstract 2: (258)** Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Prognostic Factors and Recursive Partitioning Analysis for Overall Survival

10:40 – 10:50 hs. Dr. Carlos Cardiello, Hospital Militar, Buenos Aires

- **Abstract 3: (260)** Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/ RTOG 0129 and 0522
- **Abstract 4: (261)** Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study

10:50 – 11:00 hs. Dr. Diego Fernández, Centro Médico Dean Funes, Córdoba

- **Abstract 5: (257)** Optimal Treatment Selection of Stereotactic Body Radiation Therapy and Intensity Modulated Radiation Therapy for Reirradiation of Head and Neck Cancer: A Multi-institution Comparison
- **Abstract 6: (259)** Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Improved Risk-benefit Profile in the Modern Era

11:00 – 11:10 hs. Dra. Daniela Bejarano, Vidt Centro Médico, Buenos Aires

- **Abstract 7: (263.5)** Phase 2 Trial of Induction Chemotherapy Followed by Attenuated Chemoradiation Therapy for Human Papillomavirus-positive Locally Advanced Squamous Cell Carcinoma of the Oropharynx
- **Abstract 8: (187)** Cetuximab-Based Bioradiation Therapy Versus Cisplatin-based Chemoradiation Therapy in the Definitive Treatment of Locally Advanced Oropharyngeal Squamous Cell Carcinoma

11:10 – 11:50 hs. Mesa de Discusión

Coordinador: Dr. Marcos David Pereira

Dra. Cecilia Coll (RT), Dr. Carlos Cardiello (RT),

Dr. Diego Fernández (RT), Dra. Daniela Bejarano (RT)

Dr. Pedro Saco, Cirugía Oncológica, Hospital Austral, Buenos Aires

Dr. Raúl Giglio, Oncología Clínica, Instituto Ángel Roffo, Buenos Aires

11:50 – 12:20 hs. Intervalo Café

12:20 – 13:50 hs. Módulo 9: Ginecológico

12:20 – 12:25 hs. Presidente:

Dra. Estela Broda, Vidt Centro Médico, Buenos Aires

Coordinadora:

Dra. Higinia Cardenes, Weill Cornell University, New York, USA

Disertantes:

12:25 – 12:40 hs. Dr. Gustavo Sarria, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú

- **Abstract 1: (5)** A Phase 3 Randomized Trial Comparing Patient-reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy
- **Abstract 2: (24)** Phase 3 Randomized Trial of Comparing Chemoradiation Therapy Versus Radiation Therapy Alone in Lymph Node–negative Patients With Early-stage Cervical Cancer Following Radical Hysterectomy
- **Abstract 3: (25)** Nodal Failure After Chemoradiation and Magnetic Resonance Imaging Guided Adaptive BT in Cervical Cancer: A Subanalysis Within Embrace

12:40 – 12:50 hs. Dr. Pablo Menéndez, Instituto Ángel Roffo, Bs. As.

- **Abstract 4: (27)** Phase 2 Multicenter Clinical Trial of Bone Marrow–sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage IB-IVA Cervical Cancer
- **Abstract 5: (28)** Computed Tomography Consensus Clinical Target Volume Contouring for Intensity Modulated Radiation Therapy in Intact Cervical Carcinoma

12:50 – 13:00 hs. Dra. Marcela de la Torre, Centro CDT, Buenos Aires

- **Abstract 6: (108)** National Cancer Data Base Analysis of Uterine Carcinosarcoma (UC): Improvement in Survival With the Use of Radiation Therapy
- **Abstract 7: (109)** Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

13:00 – 13:10 hs. Dr. Álvaro Luongo Gardi, COR, Montevideo, Uruguay

- **Abstract 8: (110)** Implication of Adjuvant Radiation Therapy and Dose-Response Relationship for Margin-positive Vulvar Squamous Cell Carcinoma
- **Abstract 9: (111)** Impact of Cumulative Radiation Doses to Vagina on Late Toxicity and Sexual Quality of Life in Patients Treated With Postoperative Adjuvant Radiation Therapy for Cervical Cancer

13:10 – 13:50 hs. Mesa de Discusión

Coordinadora: Dra. Higinia Cardenes

Dra. Estela Broda (RT), Dr. Gustavo Sarria (RT), Dr. Pablo Menéndez (RT),

Dra. Marcela de la Torre (RT), Dr. Álvaro Luongo Gardi (RT)

Dra. Perrota Myriam, Ginecología, Hospital Italiano, Buenos Aires

Dr. Juan Lacava, Oncología Clínica, Instituto Oncohematología, Neuquén

13:50 – 14:35 hs. Conferencia Varian: Disertante y Tema a confirmar

14:35 – 15:35 hs. Lunch – Invitación SATRO

15:35 – 17:00 hs. Módulo 10: Sistema Nervioso Central

15:35 – 15:40 hs. Presidente: Dr. Eduardo Fernández, 21st Century Oncology, USA

Coordinador: Dra. Ana Mabel Martínez, Vidt Centro Médico, Bs As

Disertantes:

15:40 – 15:55 hs. Dr. Eduardo Weltman, H. Israelita Albert Einstein, San Pablo, Brasil

- **Abstract 1: (128)** Deferring Radiation Therapy for Brain Metastases in Patients with EGFR-mutant Non-small Cell Lung Cancer: A Multi-institutional Analysis
- **Abstract 2: (58)** Treatment of Cerebral Radiation Necrosis with Nerve Growth Factor—A Prospective, Randomized, Controlled Phase 2 Study
- **Abstract 3: (204)** Omission of Radiation Therapy for Low-grade Gliomas: Molecular and Radiographic Correlates of Treatment Response and Disease Progression on a Phase 2 Clinical Trial of Adjuvant Temozolomide

15:55 – 16:05 hs. Dr. Jorge Sar, Vidt Centro Médico, Buenos Aires

- **Abstract 4: (205)** Hippocampal Dosimetry Predicts for Cancer-related Cognitive Impairment in Patients Treated With Cranial Radiation Therapy: Dosimetric Results of a Prospective Clinical Trial
- **Abstract 5: (126)** Does Whole-brain Radiation Therapy for Oligometastatic Brain Metastases Translate into a Survival Benefit for Patients with a Limited Competing Risk from Extracranial Disease? A Secondary Analysis of EORTC 22952-26001

16:05 – 16:20 hs. Dr. Lucas Causa, Centro Médico Dean Funes, Córdoba

- **Abstract 6: (3)** Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study
- **Abstract 7: (210)** Mibefradil Dihydrochloride with Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial
- **Abstract 8: (1039)** Multi-institutional Competing Risks Analysis Predicting Distant Brain Failure and Salvage Patterns After Upfront Radiosurgery without Whole-Brain Radiation Therapy for Brain Metastasis

16:20 – 17:00 hs. Mesa de Discusión

Coordinadora: Dra. Ana Mabel Martínez

Dr. Eduardo Weltman (RT), Dr. Jorge Sar (RT), Dr. Lucas Causa (RT)
Dra. Alejandra Rabadan, Neurocirugía, Inst. Alfredo Lanari, UBA, Bs. As.
Dr. Diego Hernández (RT), Hospital Naval, Buenos Aires
Dr. Alejandro Muggeri, Oncología Clínica, Instituto FLENI, Buenos Aires

17:00 – 17:30 hs. *Intervalo Café*

17:30 – 18:55 hs. Módulo 11: Genitourinario

17:30 – 17:35 hs. Presidente: Dr. Jorge Chiozza, Vidt Centro Médico, Buenos Aires

Coordinador: Dra. Carolina Chacon, Instituto Alexander Fleming, Bs. As.

Disertantes:

17:35 – 17:50 hs. Dr. Eduardo Fernández, 21st Century Oncology, USA

- **Abstract 1: (4)** NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-risk Prostate Cancer: Prostate-specific Quality of Life Results
- **Abstract 2: (71)** Randomized Trial of Hypofractionated Dose-escalated Intensity Modulated Radiation Therapy Versus Conventionally Fractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer
- **Abstract 3: (74)** Five-year Outcomes from a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-risk Prostate Cancer

17:50 – 18:05 hs. Dr. Pablo Castro Peña, Instituto Marie Curie, Córdoba

- **Abstract 4: (7)** Initial Report of NRG Oncology/ RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-risk Prostatic Carcinoma
- **Abstract 5: (312)** Long-term Androgen Deprivation, with or without Radiation Therapy, in Locally Advanced Prostate Cancer: Results from a Phase 3 Randomized Study After 7.3 Years Median Follow-up
- **Abstract 6: (314)** Androgen Deprivation and High-dose Radiation Therapy in Prostate Cancer: Report on Late Toxicity from DART 01/05 Randomized Phase III Trial

18:05 – 18:15 hs. Dra. Carmen Castro, Hospital Alemán, Buenos Aires

- **Abstract 7: (251)** Staging of Biochemically Relapsing Prostate Cancer Using the Positron Emission Tomography Tracer Fluciclovine F18
- **Abstract 8: (228)** Prostate Cancer-specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy

18:15 – 18:55 hs. Mesa de Discusión

Coordinador: Dra. Carolina Chacon

Dr. Jorge Chiozza (RT), Dr. Eduardo Fernández (RT),

Dr. Pablo Castro Peña (RT), Dra. Carmen Castro (RT)

Dr. Marcelo Blanco Villalba, Oncología Clínica, Centro Médico Austral

Dr. Luis Montes de Oca, CDU, Buenos Aires (A Confirmar)

Dr. Carlos Scorticati, Hospital de Clínicas, Bs. As. (A Confirmar)

18:55 – 19:30 hs. Módulo 12: Biología

18:55 – 19:00 hs. Presidente: Dr. Gonzalo Mandiola, CIO Tandil, Buenos Aires

Coordinador: Dra. Mabel Sardi, Instituto Mevaterapia, Buenos Aires

Disertantes:

19:00 – 19:10 hs. Dra. Catalina Pogany, Instituto Ángel Roffo, Buenos Aires

- **Abstract 1: (91)** Circulating Cell-free Human Papillomavirus DNA as a Marker of Treatment Outcome in Patients with HPV-positive Squamous Cell Head and Neck Cancer After Radio(chemo) Therapy
- **Abstract 2: (6)** Identification and Validation of Intrinsic Subtypes of Prostate Cancer

19:10 – 19:20 hs. Dra. Alba Güerci, Universidad Nacional de la Plata, Bs. As.

- **Abstract 3: (92)** CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
- **Abstract 4: (201)** Suppression of Major Histocompatibility Complex (MHC) Class I and II Mediates Resistance to Anti-PD-1 in Lung Adenocarcinoma Tumors that Can Be Overcome by Radiation Therapy

19:20 – 19:30 hs. Comentarios Finales Dra. Mabel Sardi

19:30 – 20:00 hs. Entrega de Diplomas de Recertificación en Radioterapia

Prof. Dr. Carlos Mercau, Presidente CRAMA

Dra. Luisa Rafailovici, Presidente SATRO

Dra. Estela Broda, Vicepresidente SATRO

Dra. Mabel Sardi, Secretaria General SATRO

Dr. Ricardo Alva, Comité Científico SATRO